April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Plasma Lutein And Zeaxanthin And The Risk For Age-related Maculopathy: The Alienor Study
Author Affiliations & Notes
  • Benedicte Merle
    INSERM U897, Bordeaux, France
    Universite Victor Segalen Bordeaux 2, Bordeaux, France
  • Marie-Noelle Delyfer
    Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Service d’Ophtalmologie, CHU de Bordeaux, Bordeaux, France
  • Jean-François Korobelnik
    INSERM U897, Bordeaux, France
    Service d’Ophtalmologie, CHU de Bordeaux, Bordeaux, France
  • Marie-Benedicte Rougier
    Service d’Ophtalmologie, CHU de Bordeaux, Bordeaux, France
  • Joseph Colin
    Universite Victor Segalen Bordeaux 2, Bordeaux, France
    Service d’Ophtalmologie, CHU de Bordeaux, Bordeaux, France
  • Florence Malet
    Service d’Ophtalmologie, CHU de Bordeaux, Bordeaux, France
  • Melanie Le Goff
    INSERM U897, Bordeaux, France
    Universite Victor Segalen Bordeaux 2, Bordeaux, France
  • Jean-François Dartigues
    INSERM U897, Bordeaux, France
    Universite Victor Segalen Bordeaux 2, Bordeaux, France
  • Pascale Barberger-Gateau
    INSERM U897, Bordeaux, France
    Universite Victor Segalen Bordeaux 2, Bordeaux, France
  • Cecile Delcourt
    INSERM U897, Bordeaux, France
    Universite Victor Segalen Bordeaux 2, Bordeaux, France
  • Footnotes
    Commercial Relationships  Benedicte Merle, None; Marie-Noelle Delyfer, Théa (C); Jean-François Korobelnik, Alcon (C), Bausch & Lomb (C), Bayer Pharma (C), Novartis (C), Théa (C); Marie-Benedicte Rougier, Merk Serono (C), Théa (C); Joseph Colin, None; Florence Malet, None; Melanie Le Goff, None; Jean-François Dartigues, Eisai (C), Ipsen (C), Janssen (C), Lundbeck (C), Novartis (C); Pascale Barberger-Gateau, Aprifel (C), Danone Institute (C), lecture fees Bausch & Lomb (C), Lesieur (C), Vifor Pharma (C); Cecile Delcourt, Bausch&Lomb (C), Novartis (C), Pfizer (C), Théa (C)
  • Footnotes
    Support  Théa, Fondation Voir et Entendre
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 96. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Benedicte Merle, Marie-Noelle Delyfer, Jean-François Korobelnik, Marie-Benedicte Rougier, Joseph Colin, Florence Malet, Melanie Le Goff, Jean-François Dartigues, Pascale Barberger-Gateau, Cecile Delcourt; Plasma Lutein And Zeaxanthin And The Risk For Age-related Maculopathy: The Alienor Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):96.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Lutein and zeaxanthin may protect against age-related maculopathy (ARM) possibly through blue light absorption and protection against oxidation. Results of epidemiological studies are inconsistent in this field. We report the associations of ARM with plasma carotenoids, measured 7 years before eye examination, in French elderly subjects

 
Methods:
 

The Alienor Study is a population-based study on nutrition and age-related eye diseases. 963 subjects had an eye examination from September 2006 to May 2008 in Bordeaux (France). ARM was classified from colour photographs in five exclusive stages: late neovascular ARM; late atrophic ARM (geographic atrophy); early ARM2 (large soft indistinct drusen and/or reticular drusen and/or large distinct drusen with pigment abnormalities); early ARM1 (large soft distinct drusen alone or pigment abnormalities alone); no ARM. Plasma carotenoids were determined from the blood samples collected at baseline examination of the 3C Study (1999-2001) and kept frozen at -80°C for about 10 years. Associations were estimated using logistic Generalized Estimating Equations (GEE) models, subjects without ARM being the reference. Analyses were adjusted for age, gender, educational level, monthly income, smoking, HDL-Cholesterol, triglycerides, body mass index, cataract extraction, and gene polymorphisms ApoE4, ApoE2, CFH Y402H and LOC387715

 
Results:
 

Of 963 subjects, 662 had complete data, representing 1281 gradable eyes. After multivariate adjustment, subjects with high plasma concentration of lutein and of combined lutein and zeaxanthin were at higher risk of early ARM2 (OR=1.32, 95% confidence interval (CI): 1.04-1.66, p=0.02 and OR=1.32, CI: 1.05-1.65, p=0.02, respectively). Association with zeaxanthin was in the same direction, but did not reach statistical significance (OR=1.16, CI: 0.98-1.36, p=0.08). The other stages of ARM were not significantly associated with lutein or zeaxanthin

 
Conclusions:
 

The results of the present study are not in favour of a reduced risk for ARM with high plasma levels of lutein and zeaxanthin. They might be explained by residual confounding, in particular by sunlight exposure, which will soon be estimated in our study

 
Keywords: age-related macular degeneration • macular pigment • clinical (human) or epidemiologic studies: risk factor assessment 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×